KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Operating Leases (2019 - 2025)

Historic Operating Leases for Alnylam Pharmaceuticals (ALNY) over the last 7 years, with Q4 2025 value amounting to $270.6 million.

  • Alnylam Pharmaceuticals' Operating Leases rose 1788.96% to $270.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $270.6 million, marking a year-over-year increase of 1788.96%. This contributed to the annual value of $270.6 million for FY2025, which is 1788.96% up from last year.
  • Alnylam Pharmaceuticals' Operating Leases amounted to $270.6 million in Q4 2025, which was up 1788.96% from $223.4 million recorded in Q3 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' Operating Leases registered a high of $288.6 million during Q2 2021, and its lowest value of $223.4 million during Q3 2025.
  • Moreover, its 5-year median value for Operating Leases was $256.4 million (2023), whereas its average is $255.8 million.
  • Per our database at Business Quant, Alnylam Pharmaceuticals' Operating Leases tumbled by 831.54% in 2024 and then skyrocketed by 1788.96% in 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' Operating Leases (Quarter) stood at $281.3 million in 2021, then fell by 7.11% to $261.3 million in 2022, then fell by 6.98% to $243.1 million in 2023, then dropped by 5.58% to $229.5 million in 2024, then rose by 17.89% to $270.6 million in 2025.
  • Its last three reported values are $270.6 million in Q4 2025, $223.4 million for Q3 2025, and $224.4 million during Q2 2025.